Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus

Journal of Lipid Research

Volumn 56, Issue 12, 2015, Pages 2372-2380

  Furuhashi, Masato ^a   Hiramitsu, Shinya ^b   Mita, Tomohiro ^a   Fuseya, Takahiro ^a   Ishimura, Shutaro ^a   Omori, Akina ^a   Matsumoto, Megumi ^a   Watanabe, Yuki ^a   Hoshina, Kyoko ^a   Tanaka, Marenao ^a   Moniwa, Norihito ^a   Yoshida, Hideaki ^a   Ishii, Junnichi ^c   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hiramitsu Clinic   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipocyte ; Adipokine ; Fatty acid binding protein 4 ; Glucagon like peptide 1

Indexed keywords

FATTY ACID BINDING PROTEIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITAGLIPTIN; TRIACYLGLYCEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FABP4 PROTEIN, HUMAN; FABP4 PROTEIN, MOUSE; FATTY ACID BINDING PROTEIN;

ADIPOCYTE; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; 3T3 CELL LINE; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; MOUSE; REAL TIME POLYMERASE CHAIN REACTION;

3T3-L1 CELLS; ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MALE; MICE; REAL-TIME POLYMERASE CHAIN REACTION; SITAGLIPTIN PHOSPHATE;

EID: 84949009279     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M059469     Document Type: Article

References (55)

1. Furuhashi , M. , and G. S. Hotamisligil . 2008 . Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7 : 489 - 503 .
2. Furuhashi , M. , S. Ishimura , H. Ota , and T. Miura . 2011 . Lipid chaperones and metabolic inflammation. Int. J. Inflam. 2011 : 642612 .
3. Furuhashi , M. , S. Saitoh , K. Shimamoto , and T. Miura . 2014 . Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin. Med. Insights Cardiol. 8 : 23 - 33 .
4. Hotamisligil , G. S. , R. S. Johnson , R. J. Distel , R. Ellis , V. E. Papaioannou , and B. M. Spiegelman . 1996 . Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science . 274 : 1377 - 1379 .
5. Makowski , L. , J. B. Boord , K. Maeda , V. R. Babaev , K. T. Uysal , M. A. Morgan , R. A. Parker , J. Suttles , S. Fazio , G. S. Hotamisligil , et al . 2001 . Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7 : 699 - 705 .
6. Furuhashi , M. , R. Fucho , C. Z. Gorgun , G. Tuncman , H. Cao , and G. S. Hotamisligil . 2008 . Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J. Clin. Invest. 118 : 2640 - 2650 .
7. Furuhashi , M. , G. Tuncman , C. Z. Gorgun , L. Makowski , G. Atsumi , E. Vaillancourt , K. Kono , V. R. Babaev , S. Fazio , M. F. Linton , et al . 2007 . Treatment of diabetes and atherosclerosis by inhibiting fattyacid-binding protein aP2. Nature . 447 : 959 - 965 .
8. Xu , A. , Y. Wang , J. Y. Xu , D. Stejskal , S. Tam , J. Zhang , N. M. Wat , W. K. Wong , and K. S. Lam . 2006 . Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 52 : 405 - 413 .
9. Cao , H. , M. Sekiya , M. E. Ertunc , M. F. Burak , J. R. Mayers , A. White , K. Inouye , L. M. Rickey , B. C. Ercal , M. Furuhashi , et al . 2013 . Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab. 17 : 768 - 778 .
10. Mita , T. , M. Furuhashi , S. Hiramitsu , J. Ishii , K. Hoshina , S. Ishimura , T. Fuseya , Y. Watanabe , M. Tanaka , K. Ohno , et al . 2015 . FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Silver Spring) . 23 : 359 - 367 .
11. Ertunc , M. E. , J. Sikkeland , F. Fenaroli , G. Griffiths , M. P. Daniels , H. Cao , F. Saatcioglu , and G. S. Hotamisligil . 2015 . Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity. J. Lipid Res. 56 : 423 - 434 .
12. Lamounier-Zepter , V. , C. Look , J. Alvarez , T. Christ , U. Ravens , W. H. Schunck , M. Ehrhart-Bornstein , S. R. Bornstein , and I. Morano . 2009 . Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ. Res. 105 : 326 - 334 .
13. Aragonès , G. , P. Saavedra , M. Heras , A. Cabré , J. Girona , and L. Masana . 2012 . Fatty acid-binding protein 4 impairs the insulindependent nitric oxide pathway in vascular endothelial cells. Cardiovasc. Diabetol. 11 : 72 .
14. Xu , A. , A. W. Tso , B. M. Cheung , Y. Wang , N. M. Wat , C. H. Fong , D. C. Yeung , E. D. Janus , P. C. Sham , and K. S. Lam . 2007 . Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation . 115 : 1537 - 1543 .
15. Tso , A. W. , A. Xu , P. C. Sham , N. M. Wat , Y. Wang , C. H. Fong , B. M. Cheung , E. D. Janus , and K. S. Lam . 2007 . Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care . 30 : 2667 - 2672 .
16. Ishimura , S. , M. Furuhashi , Y. Watanabe , K. Hoshina , T. Fuseya , T. Mita , Y. Okazaki , M. Koyama , M. Tanaka , H. Akasaka , et al . 2013 . Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One . 8 : e81318 .
17. Ota , H. , M. Furuhashi , S. Ishimura , M. Koyama , Y. Okazaki , T. Mita , T. Fuseya , T. Yamashita , M. Tanaka , H. Yoshida , et al . 2012 . Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am. J. Hypertens. 25 : 1124 - 1130 .
18. Fuseya , T. , M. Furuhashi , S. Yuda , A. Muranaka , M. Kawamukai , T. Mita , S. Ishimura , Y. Watanabe , K. Hoshina , M. Tanaka , et al . 2014 . Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc. Diabetol. 13 : 126 .
19. Cabré , A. , I. L á zaro , J. Girona , J. M. Manzanares , F. Marimón , N. Plana , M. Heras , and L. Masana . 2008 . Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin. Chem. 54 : 181 - 187 .
20. Cabré , A. , I. L á zaro , J. Girona , J. M. Manzanares , F. Marimón , N. Plana , M. Heras , and L. Masana . 2008 . Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J. Lipid Res. 49 : 1746 - 1751 .
21. Yeung , D. C. , A. Xu , C. W. Cheung , N. M. Wat , M. H. Yau , C. H. Fong , M. T. Chau , and K. S. Lam . 2007 . Serum adipocyte fatty acidbinding protein levels were independently associated with carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27 : 1796 - 1802 .
22. Furuhashi , M. , S. Ishimura , H. Ota , M. Hayashi , T. Nishitani , M. Tanaka , H. Yoshida , K. Shimamoto , G. S. Hotamisligil , and T. Miura . 2011 . Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One . 6 : e27356 .
23. von Eynatten , M. , L. P. Breitling , M. Roos , M. Baumann , D. Rothenbacher , and H. Brenner . 2012 . Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler. Thromb. Vasc. Biol. 32 : 2327 - 2335 .
24. Chow , W. S. , A. W. Tso , A. Xu , M. M. Yuen , C. H. Fong , T. H. Lam , S. V. Lo , H. F. Tse , Y. C. Woo , C. Y. Yeung , et al . 2013 . Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. J. Am. Heart Assoc. 2 : e004176 .
25. Cabré , A. , I. L á zaro , J. Girona , J. M. Manzanares , F. Marimón , N. Plana , M. Heras , and L. Masana . 2007 . Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis . 195 : e150 - e158 .
26. Amori , R. E. , J. Lau , and A. G. Pittas . 2007 . Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metaanalysis. J. Am. Med. Assoc . 298 : 194 - 206 .
27. Aroda , V. R. , R. R. Henry , J. Han , W. Huang , M. B. DeYoung , T. Darsow , and B. J. Hoogwerf . 2012 . Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin. Ther. 34 : 1247 - 1258.e22 .
28. Mentlein , R. 1999 . Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85 : 9 - 24 .
29. Drucker , D. J. , and M. A. Nauck . 2006 . The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet . 368 : 1696 - 1705 .
30. Campbell , J. E. , and D. J. Drucker . 2013 . Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17 : 819 - 837 .
31. Matsuo , S. , E. Imai , M. Horio , Y. Yasuda , K. Tomita , K. Nitta , K. Yamagata , Y. Tomino , H. Yokoyama , and A. Hishida . 2009 . Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53 : 982 - 992 .
32. Kajimoto , K. , S. Takayanagi , S. Sasaki , H. Akita , and H. Harashima . 2012 . RNA interference-based silencing reveals the regulatory role of fatty acid-binding protein 4 in the production of IL-6 and vascular endothelial growth factor in 3T3-L1 adipocytes. Endocrinology . 153 : 5629 - 5636 .
33. Furuhashi , M. , T. Mita , N. Moniwa , K. Hoshina , S. Ishimura , T. Fuseya , Y. Watanabe , H. Yoshida , K. Shimamoto , and T. Miura . 2015 . Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. Hypertens. Res. 38 : 252 - 259 .
34. Das , S. S. , H. Hayashi , T. Sato , R. Yamada , M. Hiratsuka , and N. Hirasawa . 2014 . Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose. Diabetes Metab. Syndr. Obes. 7 : 185 - 194 .
35. Lamers , D. , S. Famulla , N. Wronkowitz , S. Hartwig , S. Lehr , D. M. Ouwens , K. Eckardt , J. M. Kaufman , M. Ryden , S. Muller , et al . 2011 . Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes . 60 : 1917 - 1925 .
36. Rosmaninho-Salgado , J. , A. P. Marques , M. Estrada , M. Santana , V. Cortez , E. Grouzmann , and C. Cavadas . 2012 . Dipeptidylpeptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-gamma expression. Peptides . 37 : 49 - 54 .
37. Drucker , D. J. , J. Philippe , S. Mojsov , W. L. Chick , and J. F. Habener . 1987 . Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA . 84 : 3434 - 3438 .
38. Pyke , C. , R. S. Heller , R. K. Kirk , C. Orskov , S. Reedtz-Runge , P. Kaastrup , A. Hvelplund , L. Bardram , D. Calatayud , and L. B. Knudsen . 2014 . GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology . 155 : 1280 - 1290 .
39. Panjwani , N. , E. E. Mulvihill , C. Longuet , B. Yusta , J. E. Campbell , T. J. Brown , C. Streutker , D. Holland , X. Cao , L. L. Baggio , et al . 2013 . GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE( -/- ) mice. Endocrinology . 154 : 127 - 139 .
40. Montrose-Rafizadeh , C. , H. Yang , Y. Wang , J. Roth , M. H. Montrose , and L. G. Adams . 1997 . Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J. Cell. Physiol. 172 : 275 - 283 .
41. Göke , R. , H. C. Fehmann , T. Linn , H. Schmidt , M. Krause , J. Eng , and B. Göke . 1993 . Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 268 : 19650 - 19655 .
42. Gao , W. , and W. J. Jusko . 2012 . Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab. Dispos. 40 : 990 - 997 .
43. Lamont , B. J. , and D. J. Drucker . 2008 . Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes . 57 : 190 - 198 .
44. Di Flaviani , A. , F. Picconi , P. Di Stefano , I. Giordani , I. Malandrucco , P. Maggio , P. Palazzo , F. Sgreccia , C. Peraldo , F. Farina , et al . 2011 . Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care . 34 : 1605 - 1609 .
45. Apaijai , N. , H. Pintana , S. C. Chattipakorn , and N. Chattipakorn . 2013 . Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulinresistant rats. Br. J. Pharmacol. 169 : 1048 - 1057 .
46. Satoh-Asahara , N. , Y. Sasaki , H. Wada , M. Tochiya , A. Iguchi , R. Nakagawachi , S. Odori , S. Kono , K. Hasegawa , and A. Shimatsu . 2013 . A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts antiinflammatory effects in type 2 diabetic patients. Metabolism . 62 : 347 - 351 .
47. Makdissi , A. , H. Ghanim , M. Vora , K. Green , S. Abuaysheh , A. Chaudhuri , S. Dhindsa , and P. Dandona . 2012 . Sitagliptin exerts an antinflammatory action. J. Clin. Endocrinol. Metab. 97 : 3333 - 3341 .
48. Masoodi , M. , O. Kuda , M. Rossmeisl , P. Flachs , and J. Kopecky . 2015 . Lipid signaling in adipose tissue: connecting inflammation & metabolism. Biochim. Biophys. Acta . 1851 : 503 - 518 .
49. Miyoshi , T. , M. Doi , S. Hirohata , S. Kamikawa , S. Usui , H. Ogawa , K. Sakane , R. Izumi , Y. Ninomiya , and S. Kusachi . 2011 . Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels . 26 : 408 - 413 .
50. Karpisek , M. , D. Stejskal , H. Kotolova , P. Kollar , G. Janoutova , R. Ochmanova , L. Cizek , D. Horakova , R. B. Yahia , R. Lichnovska , et al . 2007 . Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur. J. Clin. Invest. 37 : 637 - 642 .
51. Lee , M. Y. , H. F. Tse , C. W. Siu , S. G. Zhu , R. Y. Man , and P. M. Vanhoutte . 2007 . Genomic changes in regenerated porcine coronary arterial endothelial cells. Arterioscler. Thromb. Vasc. Biol. 27 : 2443 - 2449 .
52. Elmasri , H. , C. Karaaslan , Y. Teper , E. Ghelfi , M. Weng , T. A. Ince , H. Kozakewich , J. Bischoff , and S. Cataltepe . 2009 . Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J. 23 : 3865 - 3873 .
53. Iso , T. , K. Maeda , H. Hanaoka , T. Suga , K. Goto , M. R. Syamsunarno , T. Hishiki , Y. Nagahata , H. Matsui , M. Arai , et al . 2013 . Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle. Arterioscler. Thromb. Vasc. Biol. 33 : 2549 - 2557 .
54. Tanaka , M. , M. Furuhashi , Y. Okazaki , T. Mita , T. Fuseya , K. Ohno , S. Ishimura , H. Yoshida , and T. Miura . 2014 . Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction. Nephron Clin. Pract. 128 : 345 - 351 .
55. Okazaki , Y. , M. Furuhashi , M. Tanaka , T. Mita , T. Fuseya , S. Ishimura , Y. Watanabe , K. Hoshina , H. Akasaka , H. Ohnishi , et al . 2014 . Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction. PLoS One . 9 : e115429 .